{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:30:35Z","timestamp":1791379835126,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03912-0","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:55:04Z","timestamp":1747223704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical characteristics of MASLD\/MetALD\/MAFLD\/NAFLD and the relative risk analysis on metabolic disorders"],"prefix":"10.1186","volume":"25","author":[{"given":"Hong-ye","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-li","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-xia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-wen","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-liang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"9","key":"3912_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10290","key":"3912_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet (London England). 2021;397(10290):2212\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(20)32511-3.","journal-title":"Lancet (London England)"},{"key":"3912_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.20517\/2394-5079.2023.134","volume":"10","author":"C Carmen","year":"2024","unstructured":"Carmen C, Maria Luisa G, Giuseppe Guido Maria S, Luigi B, Carmela C, Francesco L, et al. Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease. Hepatoma Res. 2024;10:16. https:\/\/doi.org\/10.20517\/2394-5079.2023.134.","journal-title":"Hepatoma Res"},{"issue":"11","key":"3912_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.14309\/ajg.0000000000000433","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Henry L. The impact of obesity and type 2 diabetes on chronic liver disease. Am J Gastroenterol. 2019;114(11):1714\u20135. https:\/\/doi.org\/10.14309\/ajg.0000000000000433.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"3912_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u2013e20141. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312.","journal-title":"Gastroenterology"},{"key":"3912_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"2","key":"3912_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2018;68(2):238\u201350. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.012.","journal-title":"J Hepatol"},{"issue":"4","key":"3912_CR8","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17(4):e1003100. https:\/\/doi.org\/10.1371\/journal.pmed.1003100.","journal-title":"PLoS Med"},{"issue":"5","key":"3912_CR9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jhep.2021.01.019","volume":"74","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, Demir M, Steffen HM. Hypertension in NAFLD: an uncontrolled burden. J Hepatol. 2021;74(5):1258\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.019.","journal-title":"J Hepatol"},{"issue":"4","key":"3912_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"issue":"9","key":"3912_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and Pharmacological implications. Gut. 2020;69(9):1691\u2013705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622.","journal-title":"Gut"},{"issue":"4","key":"3912_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Reviews Gastroenterol Hepatol. 2021;18(4):223\u201338. https:\/\/doi.org\/10.1038\/s41575-020-00381-6.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"5","key":"3912_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology (Baltimore MD). 2020;71(5):1851\u201364. https:\/\/doi.org\/10.1002\/hep.31150.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"12","key":"3912_CR14","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1007\/s11606-019-05340-9","volume":"34","author":"ER Cleveland","year":"2019","unstructured":"Cleveland ER, Ning H, Vos MB, Lewis CE, Rinella ME, Carr JJ, et al. Low awareness of nonalcoholic fatty liver disease in a Population-Based cohort sample: the CARDIA study. J Gen Intern Med. 2019;34(12):2772\u20138. https:\/\/doi.org\/10.1007\/s11606-019-05340-9.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"3912_CR15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s10620-019-05700-9","volume":"65","author":"A Singh","year":"2020","unstructured":"Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, et al. Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort. Dig Dis Sci. 2020;65(4):978\u201386. https:\/\/doi.org\/10.1007\/s10620-019-05700-9.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3912_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","volume":"72","author":"JV Lazarus","year":"2020","unstructured":"Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Peric\u00e0s JM, et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J Hepatol. 2020;72(1):14\u201324. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.027.","journal-title":"J Hepatol"},{"issue":"1","key":"3912_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12072-023-10620-y","volume":"18","author":"MM Ram\u00edrez-Mej\u00eda","year":"2024","unstructured":"Ram\u00edrez-Mej\u00eda MM, Jim\u00e9nez-Guti\u00e9rrez C, Eslam M, George J, M\u00e9ndez-S\u00e1nchez N. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int. 2024;18(1):168\u201378. https:\/\/doi.org\/10.1007\/s12072-023-10620-y.","journal-title":"Hepatol Int"},{"issue":"3","key":"3912_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s12072-024-10673-7","volume":"18","author":"Z Pan","year":"2024","unstructured":"Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol Int. 2024;18(3):964\u201372. https:\/\/doi.org\/10.1007\/s12072-024-10673-7.","journal-title":"Hepatol Int"},{"issue":"1","key":"3912_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2022.0017","volume":"29","author":"C G\u00f3mez-Medina","year":"2023","unstructured":"G\u00f3mez-Medina C, Melo L, Mart\u00ed-Aguado D, Bataller R. Subclinical versus advanced forms of alcohol-related liver disease: need for early detection. Clin Mol Hepatol. 2023;29(1):1\u201315. https:\/\/doi.org\/10.3350\/cmh.2022.0017.","journal-title":"Clin Mol Hepatol"},{"key":"3912_CR20","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology (Baltimore, Md). 2022;76(5):1423\u201337. https:\/\/doi.org\/10.1002\/hep.32499","DOI":"10.1002\/hep.32499"},{"issue":"8","key":"3912_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","volume":"17","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-Related fatty liver disease. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2019;17(8):1625\u2013e331. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.033.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"1","key":"3912_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.18011","volume":"60","author":"D Kim","year":"2024","unstructured":"Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Steatotic liver disease-associated all-cause\/cause-specific mortality in the united States. Aliment Pharmacol Ther. 2024;60(1):33\u201342. https:\/\/doi.org\/10.1111\/apt.18011.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3912_CR23","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/s2468-2667(17)30003-8","volume":"2","author":"M Roerecke","year":"2017","unstructured":"Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2(2):e108\u201320. https:\/\/doi.org\/10.1016\/s2468-2667(17)30003-8.","journal-title":"Lancet Public Health"},{"key":"3912_CR24","doi-asserted-by":"publisher","unstructured":"Akahane T, Namisaki T, Kaji K, Moriya K, Kawaratani H, Takaya H, et al. Chronic alcohol consumption is inversely associated with insulin resistance and fatty liver in Japanese males. Nutrients. 2020;12(4). https:\/\/doi.org\/10.3390\/nu12041036.","DOI":"10.3390\/nu12041036"},{"issue":"4","key":"3912_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1046\/j.1365-2362.2000.00624.x","volume":"30","author":"DE Flanagan","year":"2000","unstructured":"Flanagan DE, Moore VM, Godsland IF, Cockington RA, Robinson JS, Phillips DI. Alcohol consumption and insulin resistance in young adults. Eur J Clin Invest. 2000;30(4):297\u2013301. https:\/\/doi.org\/10.1046\/j.1365-2362.2000.00624.x.","journal-title":"Eur J Clin Invest"},{"issue":"6\u20137","key":"3912_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/0006-2952(91)90197-d","volume":"41","author":"CM Yang","year":"1991","unstructured":"Yang CM, Carlson GP. Effects of ethanol on glutathione conjugation in rat liver and lung. Biochem Pharmacol. 1991;41(6\u20137):923\u20139. https:\/\/doi.org\/10.1016\/0006-2952(91)90197-d.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"3912_CR27","doi-asserted-by":"publisher","first-page":"G588","DOI":"10.1152\/ajpgi.00423.2002","volume":"284","author":"MP Guarino","year":"2003","unstructured":"Guarino MP, Afonso RA, Raimundo N, Raposo JF, Macedo MP. Hepatic glutathione and nitric oxide are critical for hepatic insulin-sensitizing substance action. Am J Physiol Gastrointest Liver Physiol. 2003;284(4):G588\u201394. https:\/\/doi.org\/10.1152\/ajpgi.00423.2002.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"3912_CR28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/liv.14414","volume":"40","author":"P Nasr","year":"2020","unstructured":"Nasr P, Fredrikson M, Ekstedt M, Kechagias S. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver International: Official J Int Association Study Liver. 2020;40(5):1069\u201378. https:\/\/doi.org\/10.1111\/liv.14414.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"9","key":"3912_CR29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.cgh.2017.04.040","volume":"15","author":"K Bj\u00f6rkstr\u00f6m","year":"2017","unstructured":"Bj\u00f6rkstr\u00f6m K, St\u00e5l P, Hultcrantz R, Hagstr\u00f6m H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2017;15(9):1461\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.040.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"3","key":"3912_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, J\u00f8rgensen SMD, Thomsen KL, M\u00f8ller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Reviews Gastroenterol Hepatol. 2019;16(3):145\u201359. https:\/\/doi.org\/10.1038\/s41575-018-0082-x.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"3912_CR31","doi-asserted-by":"publisher","first-page":"958428","DOI":"10.3389\/fphar.2022.958428","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Li L, Xu Y, Du J, Ling C. Roles of hepatic stellate cells in NAFLD: from the perspective of inflammation and fibrosis. Front Pharmacol. 2022;13:958428. https:\/\/doi.org\/10.3389\/fphar.2022.958428.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3912_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41574-019-0286-3","volume":"16","author":"W Ying","year":"2020","unstructured":"Ying W, Fu W, Lee YS, Olefsky JM. The role of macrophages in obesity-associated islet inflammation and \u03b2-cell abnormalities. Nat Reviews Endocrinol. 2020;16(2):81\u201390. https:\/\/doi.org\/10.1038\/s41574-019-0286-3.","journal-title":"Nat Reviews Endocrinol"},{"issue":"9","key":"3912_CR33","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.3390\/nu5093757","volume":"5","author":"Y Watanabe","year":"2013","unstructured":"Watanabe Y, Nagai Y, Takatsu K. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients. 2013;5(9):3757\u201378. https:\/\/doi.org\/10.3390\/nu5093757.","journal-title":"Nutrients"},{"issue":"4","key":"3912_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.2040-1124.2010.00021.x","volume":"1","author":"T Ogihara","year":"2010","unstructured":"Ogihara T, Mirmira RG. An islet in distress: \u0392 cell failure in type 2 diabetes. J Diabetes Invest. 2010;1(4):123\u201333. https:\/\/doi.org\/10.1111\/j.2040-1124.2010.00021.x.","journal-title":"J Diabetes Invest"},{"issue":"5","key":"3912_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","volume":"21","author":"C Caussy","year":"2021","unstructured":"Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep. 2021;21(5):15. https:\/\/doi.org\/10.1007\/s11892-021-01383-7.","journal-title":"Curr Diab Rep"},{"key":"3912_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.021","author":"L Chen","year":"2023","unstructured":"Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.021.","journal-title":"J Hepatol"},{"key":"3912_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-331003","author":"HH Lee","year":"2023","unstructured":"Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2023. https:\/\/doi.org\/10.1136\/gutjnl-2023-331003.","journal-title":"Gut"},{"issue":"11","key":"3912_CR38","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1111\/liv.15695","volume":"43","author":"S Ciardullo","year":"2023","unstructured":"Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver International: Official J Int Association Study Liver. 2023;43(11):2425\u201333. https:\/\/doi.org\/10.1111\/liv.15695.","journal-title":"Liver International: Official J Int Association Study Liver"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03912-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03912-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03912-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:55:04Z","timestamp":1747223704000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03912-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3912"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03912-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of NHANES was reviewed and approved by the Research Ethics Review Board of the National Center for Health Statistics. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}